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Abstract
For decades, neurologists have been advocating that anyone with acute focal deficits report immediately to the closest hospital’s
emergency room. Major advancements in the hyperacute diagnosis and treatment of stroke have justified our call-to-action
slogan of “Time is Brain”—faster therapy leads to superior outcomes. However, this mantra has been recently usurped by the
catchphrase “Stay at Home” during the coronavirus disease 2019 (COVID-19) pandemic. Fewer patients are presenting to
hospitals with acute stroke; our census is down. Presumably the etiology of this phenomenon is either strict “social distancing”
that some people may misperceive to exclude even emergent situations, or fears of contracting the virus while hospitalized. In this
Short Report, we describe the year-over-year drop in stroke volume (ischemic and hemorrhagic both) coinciding with a
paradoxical rise in acute reperfusion therapies at our university hospital. These data imply that stroke patients with mild/
moderate symptoms are most likely staying home, and not receiving urgent therapies, and correspondingly, only the most
severely disabled stroke patients are ultimately seeking and receiving help. We must remind our patients and the general public
that our services are essential and available, as stroke still remains a medical emergency, and carries a likely higher overall
mortality risk than COVID-19. As neurologists, we also must be vigilant for the atypical presentations and varied etiologies of
stroke associated with COVID-19 as well.
Keywords
stroke, acute stroke therapy, dysgeusia, anosmia, COVID-19

Short Report
An unforeseen consequence of the COVID-19 pandemic is the
sudden decrease in patients presenting to the emergency room
with acute stroke. Despite our panoply of advancements in the
hyperacute diagnosis and treatment of stroke, several comprehensive cerebrovascular centers have recently observed an
abrupt drop in the census of their stroke service. The etiology
of this presumably is either strict interpretation of “social
distancing” that some people may misperceive to exclude
even emergent situations, or fears by patients or caregivers
of contracting the virus while hospitalized. Our longstanding
call-to-action mantra of “Time is Brain” has been usurped by
“Stay at Home.”
In Florida, 20.5% of the population is 65 years of age or
older, and many states have a similarly sizeable elderly demographic. This group represents the highest COVID-19 risk and
simultaneously the highest stroke risk. Noticing an obvious
decline in our stroke census at our university-based hospital in
Tampa, we tabulated our numbers this year since the virus
began spreading rapidly in February and into March, and

compared this data to the mean number of stroke patients
we saw during February and March of 2017, 2018, and
2019. The mean number of patients during those 2-month
epochs in those years was 230; however so far in 2020, we
saw only 194 during these 2 months, and April has trended
even lower. Paradoxically, however, the rate of stroke alerts at
our facility during this period that received acute reperfusion
therapy—either intravenous tissue plasminogen activator or
endovascular clot retrieval has risen to 29%—significantly
higher than the average rate of 21% seen between 2017 and
2019. This implies that stroke patients with mild or moderate
symptoms are most likely “Staying at Home” as only the most
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severely disabled stroke patients are ultimately seeking help—
and receiving it.
As our understanding of this pandemic evolves, data from
China, Italy, and other countries suggest that we must remain
vigilant for atypical presentations of stroke, and also for its
varied etiologies: it is hypothesized that COVID-19 may disrupt coagulation,1 provoke more large-vessel occlusions and
cardioemboli, and even invade the central nervous system
directly via the olfactory neuroepithelium, propagating from
within the olfactory bulb to provoke symptoms of anosmia and
dysgeusia.2
To adapt to this pandemic, stroke centers nationwide are
adjusting acute stroke response algorithms, order sets, and
protocols,3expanding telehealth (both inpatient and outpatient) and shifting most nonemergent inpatient testing assessments (such as transesophageal echocardiography and
extended cardiac monitoring, for example) into the outpatient
arena. Such temporary modifications may have trifold benefit:
limiting aerosolized procedures, decreasing length of stay, and
opening up beds for COVID-19 patients—of major benefit
when infection rates peak in each locality.
It is incumbent upon us as neurologists to remind the public
that stroke is a bona fide medical emergency and that the risk
of deferring such care more likely could be lethal than
COVID-19: the mortality risk for ischemic stroke is about
15% and for hemorrhagic is about 42%—both significantly
exceed that for COVID-19, currently estimated at approximately 1% to 3%.4,5Stroke should not be disregarded or marginalized during a pandemic. The public needs reassurance
now more than ever that hospitals have units for COVID-19
patients already preprepared and separate from everyone
else—so that emergencies such as stroke (and heart attack)
can still receive optimal treatment in a timely and safe
manner. This may mitigate the COVID-19 collateral damage
of at-home stroke that forfeits top-line treatment during
the pandemic. By modifying best practices in the hospital and
amplifying this message to the public, we can encourage highest risk individuals to realize that our vital slogan of “Time is
Brain” supersedes “Stay at Home.” Stroke treatment is an
essential service and we remain open for business.
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